Hard to Treat Diseases' (HTDS) MMR Vaccine Passed the Chinese SFDA's 'First Drug Evaluation'

SHENZHEN, China, November 17 - Hard to Treat Diseases (HTDS; www.htdsmedical.com) and its China
subsidiary Mellow Hope announce that its MMR vaccine (Measles, Mumps and
Rubella Combined Vaccine Live) had obtained a "pass" on its First Drug
Evaluation.

On November 2, 2009, State Food and Drug Administration held a Drug
Evaluation Conference to determine, whether HTDS' MMR vaccine meets the
requirements for release onto the Chinese pharmaceutical market. HTDS'
experts and representatives from the manufacturer (Serum Institute of India
Ltd.) presented the MMR attenuated vaccine to the SFDA's expert panel. The
HTDS' MMR vaccine received a "pass" on its First Drug Evaluation.

Based on the research and clinical trial results presented, the panel
concurred that the Mellow Hope's MMR vaccine had a good safety profile,
therefore, the vaccine will undergo further inquiry for the final SFDA
approval. The First Drug Evaluation panel will submit the results for final
approval. This approval will secure HTDS the production license for MMR
vaccine.

Thrilled by the results, HTDS' CEO Terry Yuan said "We got the first
"Pass" through this conference and this gives us much confidence to get the
final approval. Now we are actively preparing for the clinical trial protocol
designed exactly as per Chinese actual conditions. Taking the booster
immunization into account, it is estimated that the market size in China will
be 60 million doses per year."

Hard to Treat Diseases (HTDS) operates two medical subsidiaries in Europe
and Mainland China. HTDS is a parent company with operations in East European
Serbia based pharmaceutical company Slavica Bio Chem Co. and in China Mellow
Hope Inc.

In other company news, the issuer also brings attention to certain news
which was released by its partner Zhejiang Tianyuan Bio-Pharmaceutical Co,
thus by default (Novaris becoming the new partner after the merger) where
amongst other things Zhejiang Tianyuan Bio-Pharmaceutical Co disclosed a
huge H1N1 sale to Chile. HTDS can confirm (and will provide updates shortly)
that it has a role in that transaction with substantial gains to HTDS.

To receive future updates via email, including quarterly newsletters and
company updates that may not be newsworthy, however important to the reader
and followers of the company, please sign up today free at
www.minamargroup.com/updates

Safe Harbor Statement

Information in this news release may contain statements about future
expectations, plans, prospects or performance of Hard to Treat Diseases Inc.
that constitute forward-looking statements for purposes of the Safe Harbor
Provisions under the Private Securities Litigation Reform Act of 1995. The
words or phrases "can be", "expects", "may affect", "believed", "estimate",
"project" and similar words and phrases are intended to identify such
forward-looking statements. Hard to Treat Diseases Inc. cautions you that any
forward-looking information provided by or on behalf of Hard to Treat
Diseases Inc. is not a guarantee of future performance. None of the
information in this press release constitutes or is intended as an offer to
sell securities or investment advice of any kind. Hard to Treat Diseases
Inc.'s actual results may differ materially from those anticipated in such
forward-looking statements as a result of various important factors, some of
which are beyond Hard to Treat Diseases Inc.'s control. In addition to those
discussed in Hard to Treat Diseases Inc.'s press releases, public filings,
and statements by Hard to Treat Diseases Inc.'s management, including, but
not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of
its existing capital resources, Hard to Treat Diseases Inc.'s ability to
raise additional capital to fund future operations, Hard to Treat Diseases
Inc.'s ability to repay its existing indebtedness, the uncertainties involved
in estimating market opportunities, and in identifying contracts which match
Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such
forward-looking statements are current only as of the date on which such
statements were made. Hard to Treat Diseases Inc. does not undertake any
obligation to publicly update any forward-looking statement to reflect
events or circumstances after the date on which any such statement is made or
to reflect the occurrence of unanticipated events.

For further information: For any investor relations matters, please
contact www.minamargroup.net/helpdesk; Investor Relations Department
Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters,
www.minamargroup.com (HTDS)

Jeffrey Allen, +1(647)-426-1640

Jeffrey Allen, +1(647)-426-1640